CDKN2A and non-small cell lung carcinoma: This led us to speculate that p16 positive expression of partial patients with SqCC could be associated with other mechanisms, such as p16 promoter methylation, which is a general epigenetic alteration that has been previously shown to be involved in NSCLC.22